Flag Ship Acquisition Corp PMI
- Market cap
- $11.1M
- P/E
- 0.2×
Follow PMI
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | 82.50 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | — | 684.00 |
High Price
|
|||
| — | — | — | — | — | — | — | — | 75 | 75 |
Employees
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | 4 | 5 |
Revenue
|
|||
| — | — | — | — | — | — | — | — | (2.55%) | (4.13%) |
Gross Margin
|
|||
| — | — | — | — | — | — | — | — | (21) | (27) |
EBT
|
|||
| — | — | — | — | — | — | — | — | (479.85%) | (545.89%) |
EBT Margin
|
|||
| — | — | — | — | — | — | — | — | (21) | (27) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | 3 | 5 |
Depreciation
|
|||
| — | — | — | — | — | — | — | — | 27.63 | 6.82 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | (149.50) | (37.50) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | — | (74.73) | (21.63) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | — | (74.73) | (21.63) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | — | (149.38) | 5.23 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | 0 | 1 |
Shares
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | — | 9.41 | 12.84 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 16.74 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | — | 10.90 | 10.73 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | — | (4.47) | (3.38) |
EV/FCF
|
|||
| — | — | — | — | — | — | — | — | (12) | (16) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | (12) | (16) |
FCF
|
|||
| — | — | — | — | — | — | — | — | (26) | 2 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | 5 | 1 |
Total Debt
|
|||
| — | — | — | — | — | — | — | — | 5 | (10) |
Net Debt
|
|||
| — | — | — | — | — | — | — | — | (24) | 4 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (155.84%) |
ROA
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 134.30% |
ROE
|
|||
Flag Ship Acquisition Corp peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| IRIX IRIDEX Corporation | $11.1M | 0.0× | Compare |
| BTCY Biotricity Inc. | $10.9M | 0.0× | Compare |
| BMRA Biomerica, Inc. | $11.3M | 0.0× | Compare |
| AEMD Aethlon Medical, Inc. | $10.4M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| NMTC NeuroOne Medical Technologies Corporation | $12.1M | 0.0× | Compare |
| SINT SINTX TECHNOLOGIES, INC. | $12.5M | 0.0× | Compare |
| PETV PetVivo Holdings, Inc. | $12.9M | 0.0× | Compare |
| CTSO Cytosorbents Corporation | $13.6M | 0.0× | Compare |
Flag Ship Acquisition Corp (PMI) key facts
- Flag Ship Acquisition Corp (PMI) is a Medical Devices company in the Healthcare sector, listed on NYSE American.
- Flag Ship Acquisition Corp’s revenue for fiscal 2025 (year ended December 2025) was $4.9 million, up 12.5% from fiscal 2024.
- As of September 25, 2026, PMI traded at $4.62, a market capitalization of $11.1 million.
- Return on equity was 134.3% and debt-to-equity 0.41.
Flag Ship Acquisition Corp (PMI) Latest News
24 Aug
Philip Morris International announces a contract manufacturing collaboration with Altria. Collaboration with Altria may moderately influence PMI operations and positioning.
Flag Ship Acquisition Corp shares surged after quarterly revenue exceeded forecasts. Revenue beat produced immediate stock gains but reflects routine quarterly performance.
21 Aug
FDA authorizes ZYN ULTRA nicotine pouches for Flag Ship Acquisition Corp (PMI) after scientific review. FDA clearance for ZYN ULTRA opens new product sales channel for PMI in nicotine pouches.
19 Aug
Flag Ship Acquisition Corp (PMI) Picard Medical reported second quarter 2026 financial results. Quarterly earnings reports provide updated performance metrics that can shift investor views on operations and valuation.
27 Jul
PMI U.S. opens $1.2 billion Aurora Campus to strengthen U.S. manufacturing and export capabilities. Major $1.2 billion campus opening expands manufacturing capacity and export reach.
15 Jul
Artificial Organs publishes independent commentary on Picard Medical and SynCardia's Emperor Total Artificial Heart Program. Commentary on Emperor Total Artificial Heart Program can moderately shape perceptions of related technology and company positioning.
16 Jun
Picard Medical and SynCardia will present new in vivo Emperor Total Artificial Heart data and patient outcome research at ASAIO 2026. Conference data presentation on artificial heart device signals moderate product innovation progress without assured major market shifts.
2 Jun
Picard Medical / SynCardia completed successful next-generation preclinical implant studies advancing its Emperor Total Artificial Heart program. Successful preclinical milestones directly advance the company's core artificial heart product toward regulatory and commercial stages.
21 May
Picard Medical / SynCardia reported first quarter 2026 financial results. Quarterly results update revenue and operations for a small medical device firm and can modestly move sentiment.
22 Apr
Picard Medical / SynCardia reports revenue growth from top-line results for Q1 2026. Revenue growth by the acquisition target boosts Flag Ship Acquisition Corp (PMI) merger value and investor sentiment.
20 Apr
Philip Morris International's IQOS heated tobacco system retains FDA Modified Risk Tobacco Product authorization, enabling continued marketing of reduced exposure and risk claims versus combustible cigarettes. FDA retention of MRTP status for IQOS strengthens Philip Morris' smoke-free transition strategy and boosts investor confidence in its core growth product.
IQOS from Philip Morris International (PMI) collaborates with audio innovator Devialet on 'Soundsorial Design,' integrating advanced sound technology into IQOS devices for a multisensory smoking experience. IQOS-Devialet partnership innovates product design for PMI's core smoke-free platform, moderately enhancing competitive appeal and user engagement.
17 Apr
Philip Morris International announces U.S. FDA reauthorization of IQOS as a Modified Risk Tobacco Product. FDA reauthorization allows IQOS marketing with reduced disease risk claims, fundamentally transforming PMI's U.S. market position and long-term smoke-free growth.
16 Apr
Picard Medical / SynCardia to present next-generation Total Artificial Heart platform at ISHLT 2026 in Toronto, highlighting advancements for Flag Ship Acquisition Corp (PMI). Showcasing next-gen artificial heart at premier transplant conference advances product pipeline and elevates PMI's medtech competitive positioning.
15 Apr
Picard Medical and SynCardia showcased a successful Total Artificial Heart bridge-to-transplant case for a pediatric patient at Texas Children's Hospital. Pediatric clinical success at Texas Children's Hospital validates SynCardia's Total Artificial Heart, boosting PMI's investor sentiment and growth trajectory.
31 Mar
Philip Morris International released its Value Report 2025, themed 'change in motion,' outlining strategic shifts and value creation plans. Value Report 2025 signals major strategic changes that could significantly boost Philip Morris International's future performance and investor sentiment.
25 Mar
Flag Ship Acquisition Corp (PMI) released highlights from its Q4 earnings call, covering financial results, performance metrics, and forward-looking statements. Q4 earnings call highlights detail financial outcomes and strategic guidance, poised to significantly sway investor sentiment and stock trajectory.
Picard Medical reported full year 2025 financial results. Full-year financial results directly impact financial performance, investor sentiment, and stock trajectory for Flag Ship Acquisition Corp (PMI).
23 Mar
Perseverance Metals closed the $4.7M second and final tranche of its private placement, bringing total gross proceeds to $8.2M for Flag Ship Acquisition Corp (PMI). Raising $8.2M through private placement provides significant capital to fuel Flag Ship Acquisition Corp (PMI)'s acquisition strategy and operations.
20 Mar
Picard Medical and SynCardia will present their next-generation Emperor Total Artificial Heart technology at the American College of Cardiology’s Annual Scientific Session. Showcasing advanced artificial heart technology at a premier cardiology conference enhances visibility, credibility, and potential investor interest for PMI.
19 Mar
Picard Medical and SynCardia announce their second successful Total Artificial Heart bridge to transplant at UCSF Health, demonstrating reliable performance in critical cardiac cases. Second successful Total Artificial Heart procedure at a top hospital validates the technology and significantly boosts PMI's clinical credibility and investor appeal.
17 Mar
Picard Medical and SynCardia announced a successful four-year bridge-to-transplant using SynCardia Total Artificial Heart support, highlighting long-term efficacy in advanced heart failure patients. Four-year bridge-to-transplant success with TAH validates long-term device performance, driving significant positive investor sentiment and strategic value for PMI.
2 Mar
Picard Medical and SynCardia showcased leadership in Total Artificial Heart Therapy at the Technology and Heart Failure Therapeutics Conference. Showcasing leadership in artificial heart therapy at a major conference enhances PMI's competitive positioning and investor sentiment.
23 Feb
Leading heart transplant centers convened in Houston for Picard Medical/SynCardia’s Total Artificial Heart surgical training. Training with top centers signals advancing clinical adoption and strengthens PMI's competitive edge in artificial heart technology.
12 Feb
Picard Medical and SynCardia have successfully highlighted a bridge-to-transplant case at UCSF Health using the SynCardia Total Artificial Heart. This achievement demonstrates the effectiveness of the artificial heart in supporting patients awaiting heart transplants, showcasing advancements in cardiac care and technology. The successful case highlights significant advancements in cardiac technology that could enhance market positioning and investor sentiment for Flag Ship Acquisition Corp (PMI).
10 Feb
Picard Medical and SynCardia are set to present at the European Mechanical Circulatory Support Summit and the International Course on Mechanical Circulatory Support and New Technologies in Heart Failure, highlighting advancements in heart failure treatment technologies. The presentations may enhance product innovation and competitive positioning in the mechanical circulatory support market.
29 Jan
Picard Medical and SynCardia are set to present a webinar focused on the Emperor Fully Implantable Total Artificial Heart, hosted by DeviceTalks. This event aims to showcase advancements in heart technology and provide insights into the device's capabilities and potential impact on patients with severe heart conditions. The webinar could enhance awareness and interest in innovative heart technologies, potentially influencing market sentiment and product positioning.
13 Jan
Flag Ship Acquisition Corp (PMI) highlights the recent feature of Picard and SynCardia on the Cruxx of MedTech podcast, showcasing advancements in medical technology and innovations in heart assist devices. The discussion emphasizes the importance of these technologies in improving patient outcomes and the potential market impact of such innovations. The feature on a prominent podcast indicates significant interest and potential market shifts in the medical technology sector.
12 Jan
SynCardia has partnered with Hydrix to develop the Emperor, a next-generation total artificial heart. This collaboration aims to enhance the design and functionality of the device, which is intended to improve patient outcomes in heart failure treatment. The partnership is expected to leverage Hydrix's expertise in medical device development and SynCardia's experience in artificial heart technology. The collaboration could significantly enhance product innovation and market positioning for SynCardia's artificial heart technology.
7 Jan
Picard Medical will participate in the J.P. Morgan Healthcare Conference Week, highlighting its commitment to advancing healthcare solutions. The event is a significant platform for networking and showcasing innovations in the medical field, which could enhance Picard Medical's visibility and partnerships. Participation in a major healthcare conference can moderately influence market sentiment and potential partnerships for Picard Medical.